Validating rapid micro methods

6854933580_2c8b688306_z

Depending upon the method they may also significantly improve the accuracy of the method, the limit of detection, or other key attributes associated with the method.One of the hindrances associated with these methods has been defining what is necessary to validate these methods.Reduce costs in your supply chain with the proven, lean quality solution used by top brands to release raw materials, in-process goods and finished products from micro hold in as few as 18–24 hours.If the products you manufacture are typically free of bioburden, implementing Celsis system can provide accurate micro results in 18–24 hours, cutting days from your production cycle and helping to significantly reduce costs—without sacrificing quality.We support you in overcoming hurdles as large equipment investments, having a multi-disciplinary team available (technical, validation, quality and regulatory experts) and time constraints.The largest part of microbial assays as mentioned in the pharmacopeia such as microbial limit test and sterility test were developed at the end of the 19th century.The types of paving covered by these standards are typically made of asphalt, concrete, and bituminous materials.These road and paving standards allow geotechnical engineering firms and construction companies to examine and evaluate paving materials to ensure strength and durability towards safe application and use.

The validation and implementation of rapid and alternative microbiological methods has gained significant momentum over the past decade, with multinational firms validating new technologies for a wide range of applications including finished product release testing (e.g., sterility), environmental monitoring, in-process control, Wfi analysis and microbial identification.

Micro-organisms that will not grow in the selected growth conditions (growth media, temperature) or micro-organisms that have lost the ability to reproduction will not be detected.

Examples of pathogens that occur in a hospital environment and cannot be detected by traditional methods are .

The original document also provided an overview of technologies and their applications.

We have more than 100 current international development projects worldwide, including projects in Iraq, Jordan, Afghanistan, South Sudan, Pakistan, Colombia, Paraguay and Kenya.

Until date these methods remain the principle tests in pharmaceutical, microbiological quality control because of: Because of the reasons mentioned above, quality testing in the pharmaceutical and medical industry is limited to these simple, traditional methods.

Traditional microbiological methods however have important limitations originating from the fact that most of these methods are based on the occurrence of microbial growth to obtain a sufficient concentration for visible colonies on solid growth media or the appearance of turbidity in fluid media.

These include the Parenteral Drug Association (PDA) Technical Report Number 33, European Pharmacopoeia (Ph.

Eur.) chapter 5.1.6 and United States Pharmacopeia (USP) chapter The technical report offered guidance for evaluating, validating and implementing alternative and rapid microbiological methods to assure product quality.

When applicable, companies have submitted validation data to regulatory agencies and received approval to implement these same technologies for essential quality control uses.

For example, Novartis obtained regulatory approval from more than 50 different countries for releasing their vaccine products using a rapid ATP bioluminescence sterility test.

You must have an account to comment. Please register or login here!